Phase 2/3 trials in Xydalba clinical trial programme
The median duration of adverse events11:
Xydalba 3 days
Comparator 4 days
11 Dunne MW et al. Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies. Drug Safety. 2015